ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir
in combination with chemoradiation for locally advanced inoperable
pancreatic cancer

ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...

Description complète

Détails bibliographiques
Auteurs principaux:	Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E
Format:	Journal article
Publié:	Elsevier 2016

Documents similaires

ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
par: Wilson, J, et autres
Publié: (2017)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
par: Brunner, T, et autres
Publié: (2008)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
par: Brunner, T, et autres
Publié: (2008)

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
par: Brunner, T, et autres
Publié: (2008)

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
par: Unaí Tupinambás, et autres

New insights into the in silico prediction of HIV protease resistance to nelfinavir.
par: Dinler A Antunes, et autres
Publié: (2014-01-01)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
par: Chao Ying, et autres
Publié: (2008-02-01)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
par: Holyoake, D, et autres
Publié: (2016)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
par: Crosby, T, et autres
Publié: (2004)

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
par: Anjali K. Gupta, et autres
Publié: (2007-04-01)

Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.
par: Pranav Kumar, et autres
Publié: (2010-03-01)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
par: Mukherjee, S, et autres
Publié: (2024)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
par: Zhongli Liu, et autres
Publié: (2022-08-01)

Pneumocephalus after the Treatment of an Inoperable Superior Sulcus Tumor with Chemoradiation
par: Ashley Albert, et autres
Publié: (2017-01-01)

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
par: André FA Santos, et autres
Publié: (2011-03-01)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
par: Mukherjee, S, et autres
Publié: (2018)

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
par: Al-Assar, O, et autres
Publié: (2016)

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
par: Sudeep Gupta, et autres
Publié: (2022-04-01)

ATR targeting by the novel inhibitor VE-822 selectively sensitizes pancreatic cancer cells and tumors to radiation and chemoradiation
par: Fokas, E, et autres
Publié: (2013)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
par: Steffi Liebscher, et autres
Publié: (2017-02-01)

THE ROLE OF RADIOTHERAPY DELAY IN THE CHEMORADIATION TREATMENT FOR STAGE III INOPERABLE NON-SMALL CELL LUNG CANCER
par: E. P. Solov’eva, et autres
Publié: (2016-02-01)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
par: Christoph Driessen, et autres
Publié: (2016-03-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
par: V. B. Denisenko,, et autres
Publié: (2018-12-01)

Chemoradiation of pancreatic carcinoma
par: Erdinç Nayır, et autres
Publié: (2016-08-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
par: Jean-Guy Baril, et autres
Publié: (2003-01-01)

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo
par: Camille Bono, et autres
Publié: (2012-07-01)

Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation
par: Hilario Yankey, MD, MBA, et autres
Publié: (2024-04-01)

Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer
par: N. V. Marinichenko, et autres
Publié: (2020-12-01)

Spectrophometric Determination of Nelfinavir Mesylate
par: K. Vanitha Prakash, et autres
Publié: (2006-01-01)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
par: Alison K. Yoder, et autres
Publié: (2021-07-01)

ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
par: D. V. Gogolin, et autres
Publié: (2016-02-01)

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children
par: Léon Juan, et autres
Publié: (2006-07-01)

Induction of Suicidal Erythrocyte Death by Nelfinavir
par: Rosi Bissinger, et autres
Publié: (2015-05-01)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
par: Lenka Besse, et autres
Publié: (2023-03-01)

Nelfinavir: An Old Ally in the COVID-19 Fight?
par: Anna Gidari, et autres
Publié: (2022-12-01)

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
par: Serena Veschi, et autres
Publié: (2018-09-01)

Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
par: Kang Young-Nam, et autres
Publié: (2010-06-01)

Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer
par: Hill, E, et autres
Publié: (2016)

Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
par: Tinkl, D, et autres
Publié: (2009)

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
par: Camacho Ricardo J, et autres
Publié: (2010-08-01)